Authors: Zhongchuan Lv Yongsheng Fan Hongbing Chen Dawei Zhao
Publish Date: 2014/12/21
Volume: 36, Issue: 3, Pages: 1619-1625
Abstract
The aim of the present study was to explore serum microRNA155 miR155 expression in patients with colorectal cancer CRC and examined the potential usefulness of this molecule as a biomarker for diagnosis and prognosis in CRC Serum samples were obtained between May 2007 and March 2013 from 146 CRC patients and 60 healthy controls Serum miR155 expression levels were measured by quantitative real time reverse transcriptionpolymerase chain reaction qRTPCR Survival curves were obtained using the Kaplan–Meier method and assessed by the logrank test The receiver operating characteristic ROC curve was used for the prediction of cutoff values of the markers Serum miR155 expression level on average was upregulated in CRC patients compared with the matched healthy controls P 0001 ROC curve analysis showed that miR155 was a useful marker for discriminating cases from healthy controls with an area under the ROC curve AUC of 0776 95 confidence interval CI 0714 to 0837 P 0001 Kaplan–Meier analysis with the logrank test indicated that high serum miR155 expression had a significant impact on overall survival 382 vs 699 P 0001 and progressionfree survival 348 vs 660 P 0001 In conclusion the detection of miR155 levels in the serum might serve as a new tumor biomarker in the diagnosis and assessment of prognosis of CRC
Keywords: